Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clofoctol→

Clofoctol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
37693-01-9
Molecular formula
C21H26Cl2O
Molecular weight
365.3 g/mol
Drug class
Topical/systemic pleuromutilin-related antibacterialbacterial protein-synthesis inhibitor (historical)
Mechanism of action
Interferes with bacterial protein synthesis by binding to the 50S ribosomal subunit and inhibiting peptide-chain formation. Clinical antibacterial activity and spectrum depend on the product and local susceptibility.
Indications / reported uses
  • Historically used in selected respiratory tract infections caused by susceptible Gram-positive bacteria in countries where clofoctol was authorised; current marketed status and role are limited

Sources: NLM MeSH — Clofoctol · PubMed — Clofoctol antibacterial pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clofoctol Environmental Risk Assessment (ERA) (the Clofoctol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.